Daniel Umbricht MD

Dr. Umbricht is a graduate of the University of Zurich Medical School, Switzerland. He received his training in general psychiatry at the Zucker Hillside Hospital, New York City where he also completed a fellowship in clinical schizophrenia research under the mentorship of professors John Kane, Jeffrey Lieberman and Daniel Javitt. Dr. Umbricht has held the ranks of assistant professor at the Albert Einstein School of Medicine and associate professor at the University of Zurich.

The research of Dr. Umbricht has focused on effects of atypical antipsychotics on information processing and the role of NMDA and 5-HT2A receptors in deficient information processing and cognitive deficits in schizophrenia including studies that spanned patients, healthy volunteers, non-human primates and mice. In addition, Dr. Umbricht has conducted research in subjects at high-risk for schizophrenia that focused on predictors of transition to psychosis. In 2004 Dr. Umbricht joined Novartis Pharmaceuticals as Senior Translational Expert in Neuroscience where he lead programs in addiction, anxiety, Alzheimer’s disease and schizophrenia.

For the last nine years Dr. Umbricht has held the position of Translational Medicine Expert in Neuroscience at F. Hoffmann – La Roche Ltd. In this function Dr. Umbricht has successfully led the early clinical development of compounds in schizophrenia, autism and major depression. He is currently the head of the psychiatry/neurodevelopmental group in translational medicine neuroscience at Roche.